| (Values in U.S. Thousands) | Sep, 2020 | Jun, 2020 | Mar, 2020 | Dec, 2019 | Sep, 2019 |
| Sales | 11,260 | 3,900 | 9,670 | 11,760 | 9,440 |
| Sales Growth | +188.72% | -59.67% | -17.77% | +24.58% | +6.67% |
| Net Income | 5,390 | 120 | 4,500 | 7,350 | 6,270 |
| Net Income Growth | +4,391.67% | -97.33% | -38.78% | +17.22% | -2.49% |
Biospecifics Tech Cp (BSTC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
BIOSPECIFICS TECHNOLOGIES is engaged in the business of producing and licensing, for sale by other, a U.S. Food and Drug Administration (``FDA``) approved enzyme derived from collagenase, named Collagenase ABC, and researching, developing and clinically testing additional products derived therefrom for potential use as pharmaceuticals.
Fiscal Year End Date: 12/31